{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-053304","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2026-08-05T20:04:27+00:00","discovered_at":"2026-08-05T20:05:00.326415+00:00","generated_at":"2026-08-05T20:05:05.701396+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vistagen gets Nasdaq extension to Feb 1, 2027 to cure $1.00 bid price deficiency","bullets":["Received 180-day extension until February 1, 2027 to regain compliance with Nasdaq minimum bid price of $1.00.","Previously disclosed non-compliance on February 6, 2026; has not yet cured the deficiency.","If not compliant by end of Extension Period, Nasdaq will issue delisting notice; company may appeal.","No assurance that any appeal of a delisting determination would be successful."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-053304","json":"https://secwatch.observer/filing/0001628280-26-053304.json","markdown":"https://secwatch.observer/filing/0001628280-26-053304.md","text":"https://secwatch.observer/filing/0001628280-26-053304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026053304/0001628280-26-053304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026053304/vtgn-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:05:05.701396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}